Affichem (Group)

https://www.affichem.com

Affichem is a biotechnology company developing products in cancer and degenerative illnesses. Affichem drug candidates are based on a proprietary new family of compounds derived from sterols. The Dendrogenines A and B have demonstrated capabilities at the preclinical stage in cancer and deafness due to their properties in activating cell differentiation in neuronal and immuno-competent cells. The company expects to bring Dendrogenine A to clinical trial (phase I/II) in oncology as soon as possible. *

	Start	2002-10-11 established
	Industry	cancer drug
	Person	Silvente, Stéphane (Affichem 201508 CEO + Co-founder)

	Region	Toulouse
	Country	France
	Street	9 rue Saint Joseph
	City	31400 Toulouse
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)